Next Article in Journal
Poly(ethylene glycol)-Lipid-Conjugated Antibodies Enhance Dendritic Cell Phagocytosis of Apoptotic Cancer Cells
Previous Article in Journal
Stroke Prevention in Atrial Fibrillation: Latest Clinical Trials and Guidelines
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2012, 5(4), 398-404;

Ivabradine Prevents Heart Rate Acceleration in Patients with Chronic Obstructive Pulmonary Disease and Coronary Heart Disease after Salbutamol Inhalation

Bashkir State Medical University, Lenin Str. 3, Ufa 450000, Russia
Department of Internal Medicine II, Paracelsus Medical University, Salzburg 5020, Austria
Author to whom correspondence should be addressed.
Received: 8 February 2012 / Revised: 25 March 2012 / Accepted: 5 April 2012 / Published: 16 April 2012
(This article belongs to the Special Issue Ivabradine)
Full-Text   |   PDF [353 KB, uploaded 24 April 2012]   |  


Accelerated sinus rhythm is an important side effect of inhaled salbutamol which is especially harmful in patients with chronic obstructive pulmonary disease (COPD) and coronary heart disease (CHD). Cross-over, randomized, open label study design. 20 patients (18 males and two females) with COPD stage II–IV and comorbide CHD NYHA class I–III were included. Spirometry with 400 mg salbutamol inhalation was performed at two consecutive days of the study. Patients in group I were prescribed 5 mg ivabradine per os 3 h before salbutamol inhalation solely on the first day of the study and patients of group II received 5 mg ivabradine only on the second day of the study. Salbutamol caused a significant increase of HR by 5.5 bpm (95% CI 0.8; 10.2, p < 0.03). After ivabradine ingestion salbutamol did not change HR significantly by −2.4 bpm (−7.0; 2.3, p = 0.33). The attenuation of HR elevation by ivabradine was significant, p < 0.01. Salbutamol alone increased FEV1 by 6.0% (2.7; 9.3, p < 0.01). This effect was not impaired by ivabradine (FEV1 increase by 7.7% (2.8; 12.6, p < 0.01 versus baseline, p = 0.5 versus no ivabradine). Ivabradine 5 mg per os prevents heart rate acceleration after inhalation of 400 mg salbutamol. Ivabradine has no impact on lung function in patients with moderate-to-very-severe COPD and CHD comorbidity. View Full-Text
Keywords: ivabradine; COPD; CHD; salbutamol ivabradine; COPD; CHD; salbutamol

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Zulkarneev, R.; Zagidullin, N.; Abdrahmanova, G.; Hoppe, U.C.; Zagidullin, S. Ivabradine Prevents Heart Rate Acceleration in Patients with Chronic Obstructive Pulmonary Disease and Coronary Heart Disease after Salbutamol Inhalation. Pharmaceuticals 2012, 5, 398-404.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top